HM15275
LA-GLP/GIP/GCG · Hanmi Pharmaceutical
Weekly GLP-1/GIP/glucagon tri-agonist; Phase 2 is testing weight change and lean-mass outcomes.
Selected study results
Phase 1 · sponsor-reportedMean body-weight changeBody weight decreased 4.8% · Four weekly doses · Phase 1
Mean body-weight change · Four weekly doses
Study focus: Weight management
Participants with obesity or overweight; detailed population not provided in the cited summary · Highest tested dose sequence; source summary does not give the dose · N not included in this summary · Sponsor-reported; Phase 1. Results & methods ↗
Early sponsor-reported result after four doses; not a Phase 2 efficacy result. Detailed dose, denominator, and analysis were not included in the referenced update.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: First participant dosed in the U.S. obesity Phase 2 in December 2025.
Next: Phase 2 completion is expected in the first half of 2027.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies2 records
Phase 2 · type 2 diabetes
Weight management with type 2 diabetesA separate diabetes program is in development; it does not change the obesity stage.
U.S. obesity Phase 2 · NCT07205900
Weight management36-week study of obesity and severe obesity; weight and lean-mass outcomes.
